Capital Ideas TV: Medexus Pharmaceuticals – Growing Fast, EBITDA Positive, $27 Million to Deploy

Investors have a compelling, low-risk, specialty pharmaceutical company under their noses they may not know about. Capital Ideas Media president and publisher Mark Bunting sits down with Ken d’Entremont, CEO of Medexus Pharmaceuticals (TSXV:MDP), to find out about the company’s model of licensing existing drugs, its fast-growing revenue and operating profit, and how close the firm is to making a transformational deal using its $27 million in cash.

PLEASE SIGN UP FOR OUR FREE DAILY EMAIL, “THE MORNING NEED TO KNOW” TO HELP GET YOU READY FOR YOUR INVESTMENT DAY CAPITALIDEASMEDIA.COM

FULL DISCLOSURE: NOTHING ON THIS SITE SHOULD EVER BE CONSIDERED TO BE ADVICE, RESEARCH OR AN INVITATION TO BUY OR SELL ANY SECURITIES, PLEASE SEE MY TERMS & CONDITIONS PAGE FOR A FULL DISCLAIMER.